Program

• Review role of amyloid and tau in pathogenesis of mild Alzheimers and Mild Cognitive Impairment due to Alzheimer's; 
• Recap theoretic aspects of acetylcholine and glutamate in symptomatology of Alzheimers In the mild, moderate and severe stages; 
• Explore nutritional, metabolic, and lifestyle impact on dementia prevalence and progression.

List the CSF, blood, and radiographic tools:

• CSF amyloid (AB 42, 40, 42/40)
• CSF tau. BLOOD AB 42, 40 42/40, tau 181, 217, APOE, NfL. 
• RADIOGRAPHIC PET Amyloid and PET Tau tracers.

• Utilize office-based screening tools of Mini-Mental Status Exam/MOCA/SLUMS to address symptoms of dementia. 
• Incorporate the Clinical Dementia Rating scale to determine dementia level. 
• Rule Out non-Alzheimer etiologies via brain MRI, laboratory tests.

• FDA-approved mechanisms Aducanemab, Lecanemab, Donanemab.
• Understand various efficacy end-points utilized to achieve approval, i.e. CDR, Integrated Alzheimer disease rating scale, PET Amyloid levels, Quality of life, caregiver burden, etc. 
• Learn initiation and maintenance dosing.

Differentiate and Treat infusion-related reactions versus hypersensitivity, ARIA E & H. Screen, and Intervene of Amyloid Related Imaging Abnormality (ARIA Edema and Hemorrhage).

Learning objectives :

• Differentiate infusion-related reactions from hypersensitivity. 
• Review the natural and medication-induced prevalence of amyloid related imaging abnormality (ARIA) 
• Recognize ARIA clinical symptomatology 
• Differentiate radiographic ARIA-E from ARIA-H 
• Identify appropriate treatment candidates to mitigate risk of side effects.

Share 4 Clinical cases

Final overview & assessent with Q&A for faculty